Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05825157 · ClinicalTrials.gov registry record · NA
Evaluation of Combination Therapy for Upper Extremity Lymphedema
A NA study of Lymphedema Arm, sponsored by Stanford University.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05825157 is a NA study of Lymphedema Arm that is actively recruiting participants, run by Stanford University. The registered enrollment target is 60 participants, below the 125-participant average among 4 other Lymphedema Arm trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05825157, a NA study of Lymphedema Arm, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigate whether the addition of the Biobridge scaffold to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper extremity. Will Biobridge improve upon the low success rate of the currently practiced surgery by facilitating the lymphatic connections to the transplanted node that are crucial to its viability and function.
Conditions Studied
Interventions
- DEVICE BioBridge
Study Locations (1)
California
- Stanford Hospital and Clinics - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-11-17 |
| Est. Completion | 2029-01-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05825157
The ClinicalTrials.gov registry entry for NCT05825157 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 125-participant average among 4 other Lymphedema Arm trials with a reported enrollment target (52% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphedema Arm appearing as the primary indexed condition, and to 1 intervention - of which BioBridge is the first listed.
NCT05825157 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05825157 about?
NCT05825157 is a clinical study titled "Evaluation of Combination Therapy for Upper Extremity Lymphedema". Investigate whether the addition of the Biobridge scaffold to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper extremity. Will Biobridge improve upon the low success rate of the currently practiced surgery by facilita...
What is the current status of trial NCT05825157?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2023-11-17. Estimated completion is 2029-01-01.
What conditions does trial NCT05825157 study?
This clinical trial studies the following conditions: Lymphedema Arm.
What interventions are being tested in trial NCT05825157?
The interventions under investigation include: BioBridge (DEVICE).
Who is sponsoring clinical trial NCT05825157?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05825157 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphedema Arm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery
RECRUITING · NA
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Screening For BCRL In Targeted Therapy For Breast Cancer
ACTIVE NOT RECRUITING
-
Lymphedema Sensor Technology Development Study
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.